Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Lineage Cell Therapeutics (LCTX) Other Gross PP&E Adjustments (2016 - 2025)

Historic Other Gross PP&E Adjustments for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Q3 2025 value amounting to $2.4 million.

  • Lineage Cell Therapeutics' Other Gross PP&E Adjustments rose 7514.49% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 7514.49%. This contributed to the annual value of -$1.9 million for FY2024, which is 844.44% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Other Gross PP&E Adjustments of $2.4 million as of Q3 2025, which was up 7514.49% from $2.8 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Other Gross PP&E Adjustments' 5-year high stood at $4.0 million during Q1 2022, with a 5-year trough of -$2.0 million in Q4 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' median Other Gross PP&E Adjustments value was $1.5 million (recorded in 2021), while the average stood at $1.5 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Other Gross PP&E Adjustments skyrocketed by 26493.62% in 2022, and later crashed by 134233.13% in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Other Gross PP&E Adjustments (Quarter) stood at $74000.0 in 2021, then skyrocketed by 120.27% to $163000.0 in 2022, then tumbled by 1342.33% to -$2.0 million in 2023, then increased by 8.44% to -$1.9 million in 2024, then skyrocketed by 230.37% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $2.8 million for Q2 2025, and $2.3 million during Q1 2025.